Novo Nordisk Executives Report Share Trading in Accordance with Regulation

Novo Nordisk's board members, executives, and their associates have reported their transactions in the company's shares in accordance with Regulation No. 596/2014 on market abuse. The transactions were made by Executive Vice President Martin Holst Lange, who has given Novo Nordisk power of attorney to publish the trading. The company has issued a statement outlining the details of the transactions.

Novo Nordisk A/S, a leading global healthcare company, has disclosed insider trading activities by its Executive Vice President, Martin Holst Lange, in accordance with Regulation No. 596/2014 on market abuse. The company has published a statement detailing the transactions, which were made by Lange and for which he has given Novo Nordisk power of attorney to publish [1].

The transactions involved the sale of Novo Nordisk B shares. On August 7, 2025, Lange sold 74 shares at a price of DKK 316.7574 each, totaling DKK 23,439.50. Later the same day, Lange sold an additional 13,950 shares at a price of DKK 316.4813950 each, amounting to DKK 4,414,898.43 [1].

Novo Nordisk, headquartered in Denmark, is committed to driving change to defeat serious chronic diseases. The company employs approximately 78,400 people in 80 countries and markets its products in around 170 countries [1]. The company's shares are listed on Nasdaq Copenhagen (Novo-B) and its ADRs on the New York Stock Exchange (NVO).

The disclosed transactions are part of Novo Nordisk's transparency and compliance efforts, ensuring that all insider trading activities are reported and made public. The company continues to operate under its purpose of pioneering scientific breakthroughs, expanding access to its medicines, and working towards preventing and ultimately curing diseases.

References:
[1] https://www.manilatimes.net/2025/08/07/tmt-newswire/globenewswire/novo-nordisk-as-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons/2164240